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ABSTRACT  
Background 
Retrospective studies provide conflicting interpretations of the effect of inherited genetic factors on 
breast cancer prognosis. The primary aim of this study was to determine the impact of a germline 
BRCA1/2 mutation on outcomes in young onset breast cancer. 
Method 
Patients were recruited from 127 UK oncology centres and were eligible if aged ≤ forty years at first 
diagnosis of invasive breast cancer. BRCA1/2 mutations were identified using blood DNA collected at 
recruitment. Clinicopathological, treatment and long term outcome data were collected from 
routine medical records. The primary outcome was overall survival (OS) of all BRCA1/2 carriers vs. all 
non-carriers, assessed using Cox proportional-hazards models, or flexible parametric survival models 
(FPSMs) for models which involved time-varying hazards. Recruitment was completed in 2008; long 
term follow-up continues. 
Findings 
Between 2000-2008, 2733 women were recruited. Genotyping detected a pathogenic mutation in 
337 (12·3%) of 2733 patients (201 BRCA1, 136 BRCA2).  At a median follow-up of 8·2 years, (inter-
quartile range: 6·0 to 9·9 years), 651 (96%) of 678 deaths were due to breast cancer. There was no 
significant difference in OS between BRCA1/2 mutation carriers and non-carriers in multivariable 
analyses (OS: HR 0·96; 95% CI 0·76-1·22; p=0·76). However, in patients with triple negative breast 
cancer, (n=558), BRCA mutation carriers showed a different pattern of relapse over time compared 
to non-carriers and significantly better OS at two years, (HR 0.59 [95% CI 0·35-0·99], p=0·047).  
Interpretation 
Young onset breast cancer patients have a high mortality and those who carry a BRCA gene mutation 
have similar survival to non-carriers. BRCA carriers presenting with triple negative breast cancer may 
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have a survival advantage during the first few years after diagnosis compared to non-carriers.  
Decisions about timing of additional surgery aimed at reducing future second primary cancer risks 
should take into account prognosis associated with the first malignancy and patient preference. 
 
Funding 
Cancer Research UK, the UK National Cancer Research Network, The Wessex Cancer Trust, Breast 
Cancer Now, and PPP Healthcare Medical Trust Grant. 
Research in Context 
 
 
 
 
 
 
 
 
 
 
 
BACKGROUND   
Although only 5% of breast cancers are diagnosed in women aged less than 40 years, this age group 
experiences a high proportion of breast cancer deaths and includes a higher proportion who carry a 
Evidence before this study 
At the initiation of this cohort study (December 1999), a small number of retrospective studies 
reporting prognosis in BRCA gene carriers had been published. In December 2016, we performed 
another PubMed search for studies of BRCA1/2 mutations carriers and prognosis, using the following 
search terms:  ‘(BRCA) AND (survival or prognosis or outcome or mortality) AND (breast neoplasms 
or breast neoplasm or breast cancer or breast tumour)’. Our search was not limited by date or 
language.  References cited in review papers were hand searched for additional papers. Previous 
studies and more recent meta-analyses  have reported inconsistent effects of BRCA1 and 2 
mutations on the outcomes of early breast cancer with better, worse and the same outcomes of 
BRCA1/2 mutation carriers compared to sporadic breast cancer cases.  These conflicting results may 
be explained by methodological issues with ascertainment biases introduced by retrospective and 
selective identification of cases, incomplete genetic testing, small numbers, lack of adjustment for 
clinical variables, including treatment, and limited follow-up.  
Added value of this study 
POSH is the largest prospective cohort study to compare breast cancer outcomes of BRCA1/2 
mutation carriers with sporadic cases and is strengthened by unbiased recruitment, universal and 
central genetic testing at the end of the study and comprehensive pathological, clinical and follow-
up data. 
Implications of all the available evidence 
The overall survival of early breast cancer patients with BRCA1/2 mutations is not significantly 
different to that of patients with sporadic breast tumours when tumour and treatment factors that 
affect prognosis are taken into account. However within the triple negative (estrogen receptor 
negative, progesterone receptor negative and Her-2 receptor negative) breast cancer subgroup, 
BRCA1/2 mutation carriers may have an early survival advantage.  
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pathogenic BRCA1 or BRCA2 gene compared to older onset.1-3  Second primary breast cancers are 
more frequent in high risk gene carriers and this drives early genetic testing to inform surgical 
decision making; however it is currently unclear whether a germline BRCA1/2 mutation has 
independent prognostic implications after initial cancer diagnosis.   
BRCA1 loss of function is associated with high grade, ER (oestrogen receptor)/ PR (progesterone 
receptor)/ HER 2 (human epidermal growth factor receptor 2) negative (“triple negative”) breast 
cancer (TNBC) with a basal-like gene expression profile.4 BRCA2 associated breast tumours are 
usually high grade ER positive and HER2 negative tumours.5, 6 BRCA1 carriers have been reported to 
have enhanced sensitivity to neoadjuvant chemotherapy using cytotoxic drugs.7 
Published studies and meta-analyses have reported better, worse and the same outcomes of 
BRCA1/2 mutation carriers compared to sporadic breast cancer cases.8-14  A recent comprehensive 
meta-analysis of 66 studies of breast cancer survival in BRCA1/2 carriers compared to non-carriers or 
the general breast cancer population, which assessed study quality as well as outcome data, 
concluded that “it is not yet possible to draw evidence based conclusions about the association 
between BRCA1 and/ or BRCA2 mutation carriership and breast cancer prognosis”.12   
The primary aim of this study, Prospective Outcomes in Sporadic versus Hereditary breast cancer 
(POSH), was to determine the impact of inherited BRCA1/ 2 mutations on outcomes in young onset 
breast cancer.15, 16  
 
METHODS 
Study Design and Participants 
POSH recruited young women (aged 18 to 40) diagnosed with primary breast cancer in the United 
Kingdom between 2000 and 2008, (http://www.southampton.ac.uk/medicine/research/posh.page). 
The protocol was published in 2007.15 
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Patients recruited from 127 UK hospitals were eligible if diagnosed with invasive breast cancer aged 
40 years or younger (Appendix Table 1 pp 1-2 lists recruiting sites); the earliest date of diagnosis was 
24th January 2000 and latest diagnosis 24th January 2008. Potential recruits were identified within 12 
months of initial diagnosis of invasive breast cancer and date of diagnosis was defined as the first 
histological confirmation of invasive breast cancer and median time from diagnosis to blood draw 
was 5·5 months.  All histological subtypes, disease stages (I-IV), co-morbidities and performances 
status were permitted.  Patients with a previous invasive malignancy (with the exception of non-
melanomatous skin cancer) were excluded.  Written informed consent was obtained from all 
participants. Ethical approval was granted in 2000 (MREC 00/6/69) and the study was approved for 
recruitment as part of the UK National Cancer Research Network (NCRN) portfolio in 2002, 
subsequently the NIHR portfolio. 
 Procedures 
All patients received treatment according to local protocols. Details of personal characteristics, 
tumour pathology, disease stage, and surgical and cytotoxic treatment data were collected from 
medical records at study entry. Family history was collected by questionnaire. The BOADICEA 
algorithm [http://ccge.medschl.cam.ac.uk/boadicea/], without adjustment for pathological subtype, 
was used to estimate the probability that an individual might carry a BRCA1/2 pathogenic variant.17 
Pathology and imaging data were verified with copies of original reports from sites. For patients 
treated with neoadjuvant chemotherapy, initial tumour diameter was derived from radiological 
reports. 
 
ER, PR and HER2 receptor status of primary tumours was determined from reports of local routine 
pathology testing of diagnostic core biopsies or tumour resections for clinical use. Hormone receptor 
levels equivalent to an Allred score of ≥3 were categorised as positive. Immunohistochemical 
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staining of tissue microarrays (TMAs) in 1336 cases, during 2012 and 2016, allowed clinical source 
data for ER, PR and HER2 receptor status to be corroborated; TMA scores were used to supplement 
missing data points for these receptors.16  
DNA for genotyping was extracted from whole blood samples submitted at recruitment. A multiplex 
amplicon based library preparation system, Fluidigm Access Array™ (Fluidigm UK Ltd, Cambridge, 
UK), targeted a panel of breast cancer susceptibility genes (including BRCA1/2 and TP53) for 
massively parallel sequencing using an Illumina HiSeq2500 Next Generation Sequencing Platform 
Illumina Inc. UK, Little Chesterford, UK), details are provided in Appendix Methods 1 (pp 20-21). 
Targeted sequence capture cannot reliably identify large exonic deletions or duplications so 
multiplex ligation probe analysis (MLPA) was used in patients who met current guideline thresholds 
for clinical genetic testing.17, 18 Predicted protein truncating variants (frameshift, nonsense and 
canonical splice site and large rearrangements) plus other (mainly missense) variants unequivocally 
defined as pathogenic based on multiple lines of evidence and expert review were assigned to the 
BRCA mutation carrier group (BRCA+). All pathogenic variants were confirmed by Sanger sequencing. 
All other patients, including those carrying BRCA1/2 variants of uncertain significance or very low 
penetrance, were assigned to the same group as no mutation found (BRCA-) or excluded if found to 
carry a pathogenic variant in TP53. For the purposes of this analysis, mutations in other breast 
cancer genes were not curated. 
 
 The study protocol and patient information specified that patients would not be informed of the 
research genetic testing results. Patient information sheets gave information about seeking clinical 
genetic referral. Clinical referrals for genetic testing were made by the treating physician according 
to local protocols. Genetic test reports for study patients generated by NHS diagnostic laboratories 
were collected as part of the medical record.  
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Detailed clinical follow-up data, including date and site of disease recurrence, were obtained from 
medical records at 6, 12 months and annually thereafter until death or loss to follow-up. Patients 
were flagged in the National Health Service Medical Research Information Service for automatic 
notification of date and cause of death. We included all data received until 26 July 2016. 
Outcomes 
The primary outcome was overall survival (OS) defined as time from first diagnosis to death from any 
cause. Additional study outcomes included distant disease-free survival (DDFS) defined as time from 
first diagnosis to first distant disease, excluding local (in breast) recurrence.  
 
Statistical Analysis 
The original study sample size of a minimum of 2000 was estimated based on a prevalence of 
BRCA1/2 pathogenic mutations of 10%, and an absolute difference in two-year event rate between 
carriers and non-carriers of 10% (20% in gene carriers compared with 10% in sporadic cases).15 We 
also considered a BRCA1/2 mutation prevalence of 5% and 15% and larger sample sizes. Good 
recruitment rates and data returns allowed us to continue study recruitment beyond 2000 (actual 
sample size 3021) providing sufficient power for multivariable analyses (MVA). 
Statistical analyses were conducted according to a pre-specified plan (Appendix Documents 1 and 2, 
pp 22-31).19 The analysis population was made up of all eligible patients recruited to the cohort who 
had primary tumour and genotyping data available, were aged ≤40 years at the date of diagnosis, did 
not carry a TP53 gene, and who did not present with metastatic disease at presentation (M1 stage). 
An important pre-specified subgroup of the analysis population was patients with triple-negative 
breast cancer (TNBC population). All analyses were carried out on both the analysis population and 
TNBC population, unless specified otherwise. Key patient data were described by BRCA status, and 
formal comparisons by BRCA status were carried out using Mann-Whitney tests (for continuous 
variables) and Pearson 2-tests (for categorical variables), and were carried out on patients with 
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complete data. Kaplan-Meier plots were used to describe survival data by BRCA status at two, five 
and ten years. A two year comparison was chosen as this time-point was specified in the original 
sample size, five and ten year comparisons are commonly used and clinically relevant time points. 
Patients who did not experience an event were censored at the date of last follow-up. Hazard ratios 
(HRs) and 95% confidence intervals (CIs) for univariable analyses (UVA) and MVA (for the primary 
and secondary outcomes) were calculated using Cox proportional-hazards models, or flexible 
parametric survival models (FPSMs) for models which involved time-varying hazards.20 For each 
FPSM, varying degrees of freedom for the baseline-hazard rate and time-dependent effect were 
explored to obtain the best model fit. All missing data were assumed to be either missing at random 
or missing completely at random, and censoring assumed to be non-informative. All analyses were 
performed using Stata, version 14·2, (StataCorp, College Station, TX, USA), and multiple-imputation 
was incorporated in the MVA, generated using the mi command. Pre-specified sensitivity analyses 
included generating corresponding complete-case MVA model results. In addition, to investigate the 
degree of potential bias from time of diagnosis to registration blood draw, a MVA model adjusting 
for the time from diagnosis to blood draw was generated accordingly (TNBC population only). 
 
Role of the funding source 
The funders and their representatives had no role in the study design, data collection, analysis 
or interpretation of results or in the writing of this manuscript and the decision to submit it for 
publication. The corresponding author had full access to all of the data and the final 
responsibility to submit for publication. 
RESULTS 
Genotyping.  
Overall 337 (12·3%) of 2733 patients included in the analysis population of the cohort had either 
BRCA1 (201) or BRCA2 (136) mutations, of which 44 (12·6%) patients had large copy number variants 
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(Appendix Table 2, pp 3-7). Clinical BRCA1/BRCA2 mutation testing had occurred in 388 (14·2%) of 
the analysis population, of which 182 (46·9%) had pathogenic mutations.  
Patient characteristics 
The study recruited 3021 eligible patients, of whom 2733 (90·5%) were included in the analysis 
population, and 288 (9·5%) were excluded (M1 stage [74]; no clinical data [2]; no genotyping data 
[160], gene carriers aged 41-50 [42], or TP53 mutation carrier [10]) (Appendix Figure 1, pp 11). 
Median time from breast cancer diagnosis to study registration blood draw was 5·5 months (inter-
quartile range: 3·2-10·7 months).  There were several significant clinicopathological differences 
between BRCA1 and BRCA2 carriers and non-carriers (Table 1). Carriers had higher tumour grade and 
fewer HER2 over-amplified tumours than non-carriers. A higher proportion of BRCA1+ patients 
received breast-conserving surgery (n=106, 52·7%) compared to BRCA2+ (n=43, 31·4%) and BRCA- 
patients (n=1188, 49·6%). The most commonly used chemotherapy regimen included anthracycline 
+/- taxanes.  
Of the 2733 patients in the analysis population, 558 (20·4%) presented with TNBC (TNBC 
population). BRCA mutations were identified in 136 (24·4%) of the TNBC patients, of which 123 
(90·4%) were BRCA1. Differences in tumour characteristics between BRCA1 and BRCA2 were also 
seen in TNBCs (Table 2).  
 
Follow-up and Survival 
Median follow-up was 8·2 years, (inter-quartile range: 6·0 to 9·9 years); 91 (3·3%) of the analysis 
population were lost to follow-up. Contralateral breast tumours occurred in 151 (5·5%) patients 
overall; 37 (18·4%) in BRCA1 carriers (n=201), 17 (12·4%) in BRCA2 carriers (n=137) and 97 (4·1%) in 
non-carriers (n=2395).  Median time to contralateral breast cancer was 3·0 years, (range: 0·02 to 9·3 
years) in BRCA mutation carriers and 2·7 years, (range: 0 to 11·5 years) in non-carriers.  Seven-
hundred and fifty-two (27·5%) women developed a distant recurrence. Of the 678 deaths observed, 
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651 (96·0%) were due to breast cancer. Deaths due to non-breast malignancies, (Appendix Table 3, 
pp 8) included 6 (3%) new primary cancers in BRCA1 mutation carriers, (3 ovarian, 1 primary 
peritoneal, 1 oesophageal and 1 pancreatic) and 12 (0·5%) malignancies in non-BRCA mutation 
carriers, (4 haematological, 3 lung cancers and one each of brain, colorectal, gastric, pancreatic, 
sarcoma). There were no deaths attributed to second primary cancers amongst BRCA2 mutation 
carriers.  
OS (95% CI) in BRCA+ and BRCA- patients respectively was 97·0% (94·5% to 98·4%) versus 96·6% 
(95·8% to 97·3%) at two-years; 83·8% (79·3% to 87·5%) versus 85·0% (83·5% to 86·4%) at five-years; 
and 73·4% (67·4% to 78·5%) versus 70·1% (67·7% to 72·3%) at ten-years (Figure 1). There was no 
statistical difference even after adjusting for known prognostic factors (UVA and MVA HR [95% CI, p-
value]: 0·99 [0·78-1·24, 0·90] and 0·96 [0·76-1·22, 0·76], respectively). Similar results were found 
when comparing DDFS by BRCA+/- status (Appendix Figure 2, pp 12). Comparison of BRCA- with 
BRCA1+ or BRCA2+ for OS separately gave similar results (Appendix Figure 3 and 4, pp 13-14).  
In the TNBC sub-population, 159 (28·5%) women developed a distant recurrence, 153 (27·4%) died 
and all deaths were due to breast cancer. The estimated hazard for relapse after TNBC diagnosis 
varied over time (Figure 2). OS was significantly better for BRCA+ compared to BRCA- at two-years, 
94·8% (95% CI: 89·4% to 97·5%) vs. 91·4% (95% CI: 88·2% to 93·7%) (MVA FPSM HR [95% CI, p-value]: 
0·59 [0·35-0·99, 0·047]); the absolute difference was greatest at five-years, 81·3% (95% CI: 73·4% to 
87·1%) vs. 74·2% (95% CI: 69·7% to 78·2%) (MVA FPSM HR [95% CI, p-value]: 1·13 [0·70-1·84, 0·62]); 
and least at ten-years 72·1% (95% CI: 61·9% to 79·9%) vs. 68·8% (95% CI: 63·4% to 73·6%), (MVA 
FPSM HR [95% CI, p-value]: 2·12 [0·82-5·49, 0·12]), (Figure 3). For DDFS however the difference was 
not significant, (Appendix Figure 5, pp 15).  Inclusion of time from diagnosis to registration blood 
draw in MVA did not affect results, (Appendix Figure 6, pp 16). For all analyses, results with 
imputation were almost identical to complete case results (Appendix Tables 4 and 5, pp 9-10).  
Results from tests of proportional hazards are presented in Appendix Figure 7, pp 17. 
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Further analyses, (not included in the prior statistical analysis plan), were conducted to explore the 
possible reasons for some of our results in the TNBC group. We considered if the superior outcome 
of BRCA mutation carriers with TNBC could be due to a beneficial effect of risk reducing surgery in 
BRCA carriers so we repeated the TNBC analysis excluding 31 (5·6%) of the TNBC population (21 
BRCA+ and 10 BRCA-) who underwent bilateral mastectomy within the first year following diagnosis. 
This sensitivity MVA showed a significant difference in OS at 2 years (2-year OS% (95% CI) BRCA+ vs. 
BRCA-: 94·7% [88·6% to 97·6%] vs. 91·2% [88·0% to 93·5%]; HR [95% CI], p: 0·52 [0·29 to 0·.91], 
p=0·023). There was a slight increase in absolute survival difference for BRCA carriers at 5 years 
(from 7·1% to 8·8%), although the MVA result was not significant (5-year OS% (95% CI) BRCA+ vs. 
BRCA-: 82·6% [74·1% to 88·6%] vs. 73·9% [69·2% to 77·9%]; HR [95% CI], p: 0.98 [0·58 to 1·65], 
p=0·94)  (Appendix Figure 8, pp 18).  A further sensitivity analysis was undertaken to explore the 
observed pattern of improved survival at an early time point with apparently worse survival in the 
long term. We repeated the primary analysis in TNBC patients excluding 37 (6·6%) of patients who 
developed a new primary breast or ovarian cancer. This analysis showed that the OS HR at 10 years 
for BRCA1/2 mutation carriers versus non-carriers fell from 2·12 to 1·24 ([95% CI], p: [0·39 to 3·96], 
p=0·73; 10-year OS% (95% CI) BRCA+ vs. BRCA-: 78·4% [69·0% to 85·3%] vs. 69·3% [63·7% to 74·2%]) 
(Appendix Figure 9, pp 19).   
 
DISCUSSION 
Following a diagnosis of early breast cancer, BRCA mutation carriers are frequently offered 
additional management options including bilateral mastectomy. Any prognostic implication of 
carrying a BRCA mutation for primary treatment is important to clarify to facilitate clinician and 
patient decisions around the optimum timing of additional surgery. Furthermore, clinical trials of 
treatment specifically targeted toward BRCA gene carriers may need to take into account any effect 
of BRCA mutational status on primary treatment outcomes. We found no significant difference in OS 
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or DDFS between BRCA1/2 mutation carriers and non-carriers after breast cancer diagnosis in 
unadjusted or adjusted analyses including adjustment for ethnicity and body mass index.21, 22 
To our knowledge, this is the largest prospective study to report the prognostic implication of 
germline BRCA mutations and the only one with a pre-planned analysis in patients presenting with 
triple negative tumours.  Breast cancer mortality was high; only 2% of patients were in a screening 
programme, seven patients had been identified as BRCA carriers prior to their diagnosis, 3/7 were 
diagnosed during surveillance imaging.  Our results are in broad agreement with some previous 
studies,8-10, 23   but others have reported conflicting results.24, 25,26 Ascertainment biases introduced 
by retrospective and selective identification of cases, incomplete genetic testing, small numbers, lack 
of adjustment for clinical variables including treatment and limited follow-up likely explain many 
discrepancies although recent studies have generally used stronger methodology.11, 12  
The percentage of BRCA+ patients in the POSH cohort (12·4%) was higher than anticipated from 
historical studies of cases diagnosed ≤40 years, perhaps due to more sensitive mutation testing 
options.1 Twenty-two per cent of gene carriers (75/338) did not meet current family history or 
pathology based genetic testing guidelines.18 Only 14% of all patients had clinical genetic testing.   
The ratio of BRCA1 to BRCA2 mutations was 1·5:1 which is similar to that reported in other large 
Western population based cohorts. 2, 23 Deaths due to other malignancies were low in frequency in 
all groups reflecting the young age group; however, BRCA1 deaths included potentially preventable 
ovarian cancers at ages 41-46 years. Bilateral risk reducing mastectomy is not a necessary part of 
treating a unilateral breast cancer but unilateral mastectomy may enable breast radiotherapy to be 
omitted.  Discussion about future primary cancer prevention during primary breast cancer treatment 
must take into account individual circumstances including likely tumour prognosis and the physical 
and psychological implications of more extensive surgery.  In this cohort immediate bilateral 
mastectomy was not associated with improved survival although the reported use of risk reducing 
surgery in this cohort was low; bilateral salpingo-oophorectomy (BSO) was recorded in 32 patients 
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and bilateral mastectomies in 107 patients.27 This likely reflects the low level of clinical testing at the 
time of the study. Although risk reducing BSO is clearly highly effective at reducing ovarian cancer 
incidence, however the risk of primary peritoneal cancer is not reduced and recent studies indicate 
the previously reported effect of this procedure on future breast cancer risk in BRCA1 and BRCA2 
mutation carriers may have been overestimated because of uncorrected bias.28 
Our analysis of the 558 TNBC patients in this cohort shows an intriguing difference in the hazard for 
overall survival over the first few years after diagnosis. BRCA gene carriers were less likely to 
experience early breast cancer death than non-carriers. This early survival advantage is also 
observed amongst ovarian cancer BRCA carriers.29, 30 If real, this may reflect greater sensitivity of 
breast cancers in BRCA carriers to chemotherapy or the greater visibility of BRCA carrier cancers to 
host immune attack.31 One theory that could explain the slight survival advantage for BRCA carriers 
not undergoing immediate bilateral mastectomy, is that a major surgical intervention may 
compromise host immunity at a time when this is particularly important for eradicating 
micrometastases. This hypothesis would need further exploration due to the reduced numbers 
within this subgroup. 
Several publications have suggested that the DNA repair deficiency associated with BRCA mutations 
results in enhanced sensitivity to many chemotherapy agents, in particular higher response rates to 
platinums have been observed in both metastatic and neo-adjuvant settings.4,7 Only thirteen 
patients in this cohort were treated with platinum based adjuvant regimens for early breast cancer, 
including one BRCA1 and one BRCA2 carrier.  
Our study illustrates the high breast cancer mortality in this unscreened young population and the 
impact of known tumour and patient prognostic characteristics. Inevitably, there have been 
significant changes in the management of BRCA1/2 mutation carriers since the recruitment period of 
this study, including the exploration in trials of systemic therapies that exploit BRCA-null tumours 
including platinums and PARP inhibitors. The association of BRCA mutations with improved breast 
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cancer early outcomes in TNBC patients has the potential to influence early clinical trial results. As 
advanced genomic investigations increasingly become a part of routine oncological care, a significant 
proportion of breast cancer patients now learn their BRCA mutation status close to the time of 
diagnosis. In many cancer centres, immediate or post-chemotherapy bilateral mastectomy has 
become an almost routine recommendation for BRCA1 and BRCA2 mutation carriers regardless of 
the size or focality of the presenting tumour. In the longer term, for good prognosis breast cancers in 
particular, our data suggest that bilateral mastectomy and bilateral salpingo-oophorectomy would 
be expected to reduce deaths. Clinicians need to consider short and long term risks and benefits in 
discussing risk reducing bilateral mastectomy with patients. The number of patients in our TNBC 
group who had immediate bilateral mastectomy is small but our analysis suggests it is unlikely that 
the early bilateral mastectomy is accounting for the early survival advantage seen in the BRCA 
carriers with TNBC. With modern imaging using MRI breast screening, we conclude that patients 
who choose to delay additional surgery for one or two years until they are psychologically and 
physically recovered from their cancer treatment, can be reassured that this choice is unlikely to 
lead to any significant survival disadvantage. The importance of appropriately timed risk reducing 
bilateral salpingo-oophorectomy, for BRCA1 mutations carriers in particular, is clear but should take 
plans for further pregnancy into account. Furthermore, risk reducing bilateral salpingo-
oophorectomy in very young women will have negative health consequences as a result of 
oestrogen deprivation from an early age.  
The strengths of the POSH study include the large cohort size, low levels of missing data and young 
onset leading to a large number of BRCA1 and BRCA2 mutation carriers and high event rate ensuring 
that the study was well powered for the main outcome analysis. Our study minimises many of the 
biases in other studies by recruiting patients within the first year after diagnosis from oncology 
clinics nationally to minimise survival and selection bias and establishing BRCA carrier status for all 
patients included in the analysis. POSH participants recruited from England represented 23% of the 
available population during the recruitment period and comparison with cancer registry data has 
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confirmed that the POSH cohort is representative of the wider population.16 Comprehensive details 
of pathology have enabled us to perform a separate analysis of outcome in patients with TNBC 
tumours; this is a unique contribution to this field. We have previously reported the significant and 
independent prognostic impacts of obesity and ethnicity on long-term outcomes in this young 
patient group; and this study is the only prospective study to date to include these host factors in 
multi-variable analyses.21, 22   
Limitations of this study include the non-universal use of MLPA; we therefore cannot exclude the 
possibility that some structural variants have not been identified. However, even clinical diagnostic 
mutation testing is not 100% sensitive due to occult mutations not amenable to current methods 
(e.g. deep intronic splice variants); the investigation of BRCA1/2 gene sequences in this cohort was 
more comprehensive than in most other publications. All participants were tested for TP53 
mutations and carriers were excluded from this analysis because of the high risk of non-breast 
malignancies. We acknowledge that other breast cancer susceptibility gene variants have not been 
excluded; however these are expected to be very low in frequency and/or low penetrance and there 
is no evidence they specifically affect prognosis. We have outcome data from national flagging up to 
a median of 8·2 years. The treatment given reflects modern oncological practice with almost 90% of 
patients receiving neo/adjuvant chemotherapy, in over 95% of cases this was an anthracycline or 
anthracycline/taxane combination regimen.   
Other limitations include restriction of the main cohort of the POSH study to patients aged 40 years 
or under at the time of diagnosis in order to enrich for BRCA mutation carriers. It is possible that 
observations in young onset breast cancer patients may not translate to older ages at diagnosis.   
Progesterone receptor testing was not performed routinely in many UK centres during the period of 
recruitment and supplementary data were derived from TMAs rather than full tumour sections. The 
relevance of TNBC in terms of biology and treatment has only become apparent since the POSH 
study was designed so the study is was not powered for this as the primary outcome, perhaps 
making it more noteworthy that the main difference in outcomes between carriers and non-carriers 
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was in this sub-group. Recommendations for adjuvant treatment in the UK changed over the course 
of recruitment with taxanes being recommended for node positive disease from 2006 and adjuvant 
trastuzumab for HER2 positive breast cancer routinely available only from 2006. Although we 
specifically collected information at 5 years about risk reducing surgery, we cannot exclude the 
possibility that risk reducing mastectomy and oophorectomy may have been performed at different 
hospitals from the recruiting cancer centre, (eg. at specialist plastic surgery or gynaecological units).  
 
Conclusions 
This study confirms that patients diagnosed with invasive breast cancer aged 18-40 years have a high 
breast cancer specific mortality and a high proportion of BRCA1 and BRCA2 gene carriers. We found 
no clear evidence that either BRCA1 or BRCA2 germline mutations significantly influence breast 
cancer prognosis after adjusting for known prognostic factors. Decisions about timing of risk 
reducing surgery should take into account primary tumour prognosis and patient preference. BRCA 
carriers presenting with TNBC may have an improved survival during the first few years after 
diagnosis compared to non-carriers although immediate bilateral mastectomy does not account for 
this advantage. Finally, analysis of early outcome data from trials exploring BRCA-deficient tumour 
treatment in TNBC should be interpreted with caution in view of the likely early survival advantage 
for BRCA carriers.  
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TABLES 
Table 1 – Patient and clinicopathological information for all patients (analysis population) 
 
 
Characteristic 
All patients BRCA1+ BRCA2+ BRCA+ BRCA- p-value† 
(n=2733) (n=201) (n=137) (n=338) (n=2395)  
Age at diagnosis, in 
years 
     
BRCA+ vs BRCA- 
Median 36 35 37 36 37 p<0·0001 
Range 
18 to 40, 22 to 40, 21 to 40, 21 to 40, 18 to 40, 
BRCA1+ vs 
BRCA2+ 
IQR 34 to 38 32 to 38 33 to 38 32 to 38 34 to 39 p=0·014 
Missing 0 0 0 0 0  
Body Mass Index      BRCA+ vs BRCA- 
BMI<25kg/m2 1427 (54·2%) 114 (59·4%) 70 (52·6%) 184 (56·6%) 1243 (53·9%) p=0·48 
25kg/m2≤BMI<30kg/m
2 
714 (27·1%) 47 (24·5%) 41 (30·8%) 88 (27·1%) 626 (27·1%) 
BRCA1+ vs 
BRCA2+ 
BMI≥30kg/m2 491 (18·7%) 31 (16·1%) 22 (16·5%) 53 (16·3%) 438 (19·0%) p=0·40 
Total 2632 (100%) 192 (100%) 133 (100%) 325 (100%) 2307 (100%)  
Missing 101 (3·7%) 9 (4·5%) 4 (2·9%) 13 (3·8%) 88 (3·7%)  
Ethnicity      BRCA+ vs BRCA- 
Caucasian/white 2494 (92·4%) 178 (90·8%) 122 (91·0%) 300 (90·9%) 2194 (92·7%) p=0·28 
Black 
103 (3·8%) 10 (5·1%) 6 (4·5%) 16 (4·8%) 87 (3·7%) 
BRCA1+ vs 
BRCA2+ 
Asian 80 (3·0%) 5 (2·6%) 4 (3·0%) 9 (2·7%) 71 (3·0%) p=0·99 
Other 21 (0·8%) 3 (1·5%) 2 (1·5%) 5 (1·5%) 16 (0·7%)  
Total 2698 (100%) 196 (100%) 134 (100%) 330 (100%) 2368 (100%)  
Missing 35 (1·3%) 5 (2·5%) 3 (2·2%) 8 (2·4%) 27 (1·1%)  
Histological Grade      BRCA+ vs BRCA- 
1 156 (5·9%) 2 (1·0%) 0 2 (0·6%) 154 (6·6%) p<0·0001 
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Characteristic 
All patients BRCA1+ BRCA2+ BRCA+ BRCA- p-value† 
(n=2733) (n=201) (n=137) (n=338) (n=2395)  
2 
904 (34·0%) 16 (8·1%) 40 (31·0%) 56 (17·2%) 848 (36·4%) 
BRCA1+ vs 
BRCA2+ 
3 1598 (60·1%) 179 (90·9%) 89 (69·0%) 268 (82·2%) 1330 (57·0%) p<0·0001 
Total 2658 (100%) 197 (100%) 129 (100%) 326 (100%) 2332 (100%)  
Missing/not graded 75 (2·7%) 4 (2·0%) 8 (5·8%) 12 (3·6%) 63 (2·6%)  
ER status      BRCA+ vs BRCA- 
Negative 908 (33·4%) 151 (75·5%) 21 (15·4%) 172 (51·2%) 736 (30·9%) p<0·0001 
Positive 
1811 (66·6%) 49 (24·5%) 115 (84·6%) 164 (48·8%) 1647 (69·1%) 
BRCA1+ vs 
BRCA2+ 
Total 2719 (100%) 200 (100%) 136 (100%) 336 (100%) 2383 (100%) p<0·0001 
Missing 14 (0·5%) 1 (0·5%) 1 (0·7%) 2 (0·6%) 12 (0·5%)  
HER2 status      BRCA+ vs BRCA- 
Negative 1763 (73·1%) 164 (93·2%) 111 (88·8%) 275 (91·4%) 1488 (70·5%) p<0·0001 
Positive 
649 (26·9%) 12 (6·8%) 14 (11·2%) 26 (8·6%) 623 (29·5%) 
BRCA1+ vs 
BRCA2+ 
Total 2412 (100%) 176 (100%) 125 (100%) 301 (100%) 2111 (100%) p=0·18 
Missing 321 (11·7%) 25 (12·4%) 12 (8·8%) 37 (10·9%) 284 (11·9%)  
PR status      BRCA+ vs BRCA- 
Negative 951 (43·1%) 144 (84·2%) 23 (21·5%) 167 (60·1%) 784 (40·6%) p<0·0001 
Positive 
1257 (56·9%) 27 (15·8%) 84 (78·5%) 111 (39·9%) 1146 (59·4%) 
BRCA1+ vs 
BRCA2+ 
Total 2208 (100%) 171 (100%) 107 (100%) 278 (100%) 1930 (100%) p<0·0001 
Missing 525 (19·2%) 30 (14·9%) 30 (21·9%) 60 (17·8%) 465 (19·4%)  
*TNBC status      BRCA+ vs BRCA- 
Not TNBC 2175 (79·6%) 78 (38·8%) 124 (90·5%) 202 (59·8%) 1973 (82·4%) p<0·0001 
TNBC 
558 (20·4%) 123 (61·2%) 13 (9·5%) 136 (40·2%) 422 (17·6%) 
BRCA1+ vs 
BRCA2+ 
Total 2733 (100%) 201 (100%) 137 (100%) 338 (100%) 2395 (100%) p<0·0001 
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Characteristic 
All patients BRCA1+ BRCA2+ BRCA+ BRCA- p-value† 
(n=2733) (n=201) (n=137) (n=338) (n=2395)  
Missing 0 0 0 0 0  
Maximum tumour size 
(invasive), in mm 
     
BRCA+ vs BRCA- 
Median 22 21 25 22 22 p=0·97 
Range 
0 to 170, 1 to 140, ·5 to 92, ·5 to 140, 0 to 170, 
BRCA1+ vs 
BRCA2+ 
IQR 15 to 33 15 to 30 16 to 32 15 to 31 15 to 34 p=0·060 
Missing 156 (5·7%) 10 (5·0%) 14 (10·2%) 24 (7·1%) 132 (5·5%)  
Pathological N stage      BRCA+ vs BRCA- 
N0 1304 (48·4%) 129 (64·2%) 55 (40·7%) 184 (54·8%) 1120 (47·5%) p=0·013 
N1 
1388 (51·6%) 72 (35·8%) 80 (59·3%) 152 (45·2%) 1236 (52·5%) 
BRCA1+ vs 
BRCA2+ 
1 to 3 899 (33·4%) 43 (21·4%) 51 (37·8%) 94 (28·0%) 805 (34·2%) p<0·0001 
4 to 9 330 (12·3%) 14 (7·0%) 19 (14·1%) 33 (9·8%) 297 (12·6%) BRCA+ vs BRCA- 
10+ 159 (5·9%) 15 (7·5%) 10 (7·4%) 25 (7·4%) 134 (5·7%) p=0·019 
Total 
2692 (100%) 201 (100%) 135 (100%) 336 (100%) 2356 (100%) 
BRCA1+ vs 
BRCA2+ 
Missing 41 (1·5%) 0 2 (1·5%) 2 (0·6%) 39 (1·6%) p=0·00017 
Lymphovascular 
invasion 
     
BRCA+ vs BRCA- 
Absent 1327 (52·3%) 116 (61·1%) 58 (46·8%) 174 (55·4%) 1153 (51·8%) p=0·23 
Present 
1212 (47·7%) 74 (38·9%) 66 (53·2%) 140 (44·6%) 1072 (48·2%) 
BRCA1+ vs 
BRCA2+ 
Total 2539 (100%) 190 (100%) 124 (100%) 314 (100%) 2225 (100%) p=0·013 
Missing 194 (7·1%) 11 (5·5%) 13 (9·5%) 24 (7·1%) 170 (7·1%)  
Chemotherapy timing      BRCA+ vs BRCA- 
None 294 (10·8%) 9 (4·5%) 11 (8·0%) 20 (5·9%) 274 (11·4%) p=0·0058 
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Characteristic 
All patients BRCA1+ BRCA2+ BRCA+ BRCA- p-value† 
(n=2733) (n=201) (n=137) (n=338) (n=2395)  
Adjuvant 
2027 (74·2%) 171 (85·1%) 99 (72·3%) 270 (79·9%) 1757 (73·4%) 
BRCA1+ vs 
BRCA2+ 
Neoadjuvant 412 (15·1%) 21 (10·4%) 27 (19·7%) 48 (14·2%) 364 (15·2%) p=0·016 
Total 2733 (100%) 201 (100%) 137 (100%) 338 (100%) 2395 (100%)  
Missing 0 0 0 0 0  
Surgical Type      BRCA+ vs BRCA- 
BCS 1337 (48·9%) 106 (52·7%) 43 (31·4%) 149 (44·1%) 1188 (49·6%) p=0·30 
Mastectomy 
1373 (50·2%) 94 (46·8%) 92 (67·2%) 186 (55·0%) 1187 (49·6%) 
BRCA1+ vs 
BRCA2+ 
Nodal surgery only 7 (0·3%) 1 (0·5%) 0 1 (0·3%) 6 (0·3%) p=0·00040 
None 16 (0·6%) 0 2 (1·5%) 2 (0·6%) 14 (0·6%)  
Total 2733 (100%) 201 (100%) 137 (100%) 338 (100%) 2395 (100%)  
Missing 0 0 0 0 0  
Chemotherapy regimen      BRCA+ vs BRCA- 
None 294 (10·8%) 9 (4·5%) 11 (8·0%) 20 (5·9%) 274 (11·4%) p=0·015 
Anthracyclines 
1760 (64·4%) 145 (72·1%) 89 (65·0%) 234 (69·2%) 1526 (63·7%) 
BRCA1+ vs 
BRCA2+ 
Anthracyclines & 
Taxanes 
635 (23·2%) 45 (22·4%) 34 (24·8%) 79 (23·4%) 556 (23·2%) 
p=0·38 
Taxanes 24 (0·9%) 0 1 (0·7%) 1 (0·3%) 23 (1·0%)  
Other (includes CMF) 20 (0·7%) 2 (1·0%) 2 (1·5%) 4 (1·2%) 16 (0·7%)  
Total 2733 (100%) 201 (100%) 137 (100%) 338 (100%) 2395 (100%)  
Missing 0 0 0 0 0  
IQR=Inter-quartile range, ER=Oestrogen Receptor, HER2=Human Epidermal growth factor Receptor 2, 
PR=Progesterone Receptor, BCS=Breast Conserving Surgery. 
†Test between BRCA+ vs. BRCA- patients, and BRCA1+ vs. BRCA2+ patients (excluding patients with both 
BRCA1 and BRCA2). Mann-Whitney tests used for continuous variables and Pearson 2-tests for categorical 
variables, carried out on patients with complete data. 
* TNBC= triple negative breast cancer, defined as ER negative, HER2 negative and PR negative or unknown. 
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Table 2 – Patient and clinicopathological information for TNBC patients (TNBC population) 
 
Characteristic 
All patients BRCA1+ BRCA2+ BRCA+ BRCA- p-value† 
(n=558) (n=123) (n=13) (n=136) (n=422)  
Age at diagnosis, in 
years 
     
BRCA+ vs BRCA- 
Median 36 34 33 34 36 p=0·00056 
Range 
19 to 40, 22 to 40, 30 to 40, 22 to 40, 19 to 40, 
BRCA1+ vs 
BRCA2+ 
IQR 33 to 38 32 to 37 32 to 38 32 to 37 33 to 38 p=0·79 
Missing 0 0 0 0 0  
Body Mass Index      BRCA+ vs BRCA- 
BMI<25kg/m2 274 (50·2%) 67 (56·3%) 5 (38·5%) 72 (54·5%) 202 (48·8%) p=0·26 
25kg/m2≤BMI<30kg/m
2 
149 (27·3%) 32 (26·9%) 5 (38·5%) 37 (28·0%) 112 (27·1%) 
BRCA1+ vs 
BRCA2+ 
BMI≥30kg/m2 123 (22·5%) 20 (16·8%) 3 (23·1%) 23 (17·4%) 100 (24·2%) p=0·47 
Total 546 (100%) 119 (100%) 13 (100%) 132 (100%) 414 (100%)  
Missing 12 (2·2%) 4 (3·3%) 0 4 (2·9%) 8 (1·9%)  
Ethnicity      BRCA+ vs BRCA- 
Caucasian/white 500 (90·9%) 110 (90·2%) 9 (69·2%) 119 (88·1%) 381 (91·8%) p=0·52 
Black 
26 (4·7%) 7 (5·7%) 2 (15·4%) 9 (6·7%) 17 (4·1%) 
BRCA1+ vs 
BRCA2+ 
Asian 19 (3·5%) 3 (2·5%) 2 (15·4%) 5 (3·7%) 14 (3·4%) p=0·052 
Other 5 (0·9%) 2 (1·6%) 0 2 (1·5%) 3 (0·7%)  
Total 550 (100%) 122 (100%) 13 (100%) 135 (100%) 415 (100%)  
Missing 8 (1·4%) 1 (0·8%) 0 1 (0·7%) 7 (1·7%)  
Histological Grade      BRCA+ vs BRCA- 
1 3 (0·6%) 0 0 0 3 (0·7%) p=0·49 
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Characteristic 
All patients BRCA1+ BRCA2+ BRCA+ BRCA- p-value† 
(n=558) (n=123) (n=13) (n=136) (n=422)  
2 
30 (5·5%) 6 (4·9%) 0 6 (4·4%) 24 (5·9%) 
BRCA1+ vs 
BRCA2+ 
3 508 (93·9%) 116 (95·1%) 13 (100·0%) 129 (95·6%) 379 (93·3%) p=0·41 
Total 541 (100%) 122 (100%) 13 (100%) 135 (100%) 406 (100%)  
Missing/not graded 17 (3·0%) 1 (0·8%) 0 1 (0·7%) 16 (3·8%)  
Maximum tumour size 
(invasive), in mm 
     
BRCA+ vs BRCA- 
Median 22 20·75 23·25 21 23 p=0·17 
Range 
1 to 160, 4 to 140, 15 to 30, 4 to 140, 1 to 160, 
BRCA1+ vs 
BRCA2+ 
IQR 15 to 31 15 to 30 16 to 30 15 to 30 15 to 32 p=0·72 
Missing 35 (6·3%) 5 (4·1%) 3 (23·1%) 8 (5·9%) 27 (6·4%)  
Pathological N stage      BRCA+ vs BRCA- 
N0 341 (61·8%) 80 (65·0%) 7 (58·3%) 87 (64·4%) 254 (60·9%) p=0·46 
N1 
211 (38·2%) 43 (35·0%) 5 (41·7%) 48 (35·6%) 163 (39·1%) 
BRCA1+ vs 
BRCA2+ 
1 to 3 141 (25·5%) 26 (21·1%) 4 (33·3%) 30 (22·2%) 111 (26·6%) p=0·64 
4 to 9 45 (8·2%) 7 (5·7%) 0 7 (5·2%) 38 (9·1%) BRCA+ vs BRCA- 
10+ 25 (4·5%) 10 (8·1%) 1 (8·3%) 11 (8·1%) 14 (3·4%) p=0·044 
Total 
552 (100%) 123 (100%) 12 (100%) 135 (100%) 417 (100%) 
BRCA1+ vs 
BRCA2+ 
Missing 6 (1·1%) 0 1 (7·7%) 1 (0·7%) 5 (1·2%) p=0·68 
Lymphovascular 
invasion 
     
BRCA+ vs BRCA- 
Absent 312 (60·3%) 71 (61·2%) 4 (40·0%) 75 (59·5%) 237 (60·6%) p=0·83 
Present 
205 (39·7%) 45 (38·8%) 6 (60·0%) 51 (40·5%) 154 (39·4%) 
BRCA1+ vs 
BRCA2+ 
Total 517 (100%) 116 (100%) 10 (100%) 126 (100%) 391 (100%) p=0·19 
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Characteristic 
All patients BRCA1+ BRCA2+ BRCA+ BRCA- p-value† 
(n=558) (n=123) (n=13) (n=136) (n=422)  
Missing 41 (7·3%) 7 (5·7%) 3 (23·1%) 10 (7·4%) 31 (7·3%)  
Chemotherapy timing      BRCA+ vs BRCA- 
None 13 (2·3%) 3 (2·4%) 0 3 (2·2%) 10 (2·4%) p=0·17 
Adjuvant 
450 (80·6%) 108 (87·8%) 9 (69·2%) 117 (86·0%) 333 (78·9%) 
BRCA1+ vs 
BRCA2+ 
Neoadjuvant 95 (17·0%) 12 (9·8%) 4 (30·8%) 16 (11·8%) 79 (18·7%) p=0·074 
Total 558 (100%) 123 (100%) 13 (100%) 136 (100%) 422 (100%)  
Missing 0 0 0 0 0  
Surgical Type      BRCA+ vs BRCA- 
BCS 331 (59·3%) 69 (56·1%) 5 (38·5%) 74 (54·4%) 257 (60·9%) p=0·19 
Mastectomy 
223 (40·0%) 53 (43·1%) 7 (53·8%) 60 (44·1%) 163 (38·6%) 
BRCA1+ vs 
BRCA2+ 
Nodal surgery only 1 (0·2%) 1 (0·8%) 0 1 (0·7%) 0 p=0·014 
None 3 (0·5%) 0 1 (7·7%) 1 (0·7%) 2 (0·5%)  
Total 558 (100%) 123 (100%) 13 (100%) 136 (100%) 422 (100%)  
Missing 0 0 0 0 0  
Chemotherapy regimen      BRCA+ vs BRCA- 
None 13 (2·3%) 3 (2·4%) 0 3 (2·2%) 10 (2·4%) p=0·097 
Anthracyclines 
382 (68·5%) 91 (74·0%) 6 (46·2%) 97 (71·3%) 285 (67·5%) 
BRCA1+ vs 
BRCA2+ 
Anthracyclines & 
Taxanes 
159 (28·5%) 27 (22·0%) 7 (53·8%) 34 (25·0%) 125 (29·6%) 
p=0·086 
Taxanes 2 (0·4%) 0 0 0 2 (0·5%)  
Other (includes CMF) 2 (0·4%) 2 (1·6%) 0 2 (1·5%) 0  
Total 558 (100%) 123 (100%) 13 (100%) 136 (100%) 422 (100%)  
Missing 0 0 0 0 0  
IQR=Inter-quartile range, BCS=Breast Conserving Surgery. 
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†Test between BRCA+ vs. BRCA- patients, and BRCA1+ vs. BRCA2+ patients (excluding patients with both 
BRCA1 and BRCA2). Mann-Whitney tests used for continuous variables and Pearson 2-tests for categorical 
variables, carried out on patients with complete data.. 
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FIGURES 
Figure 1 – Overall Survival by BRCA status for all patients (analysis population) 
 
Kaplan-Meier plot by BRCA1 and/or 2 status (BRCA+/-) for Overall Survival (OS) (Panel A); and Forest Plot of 
corresponding univariable and multivariable hazard ratios by BRCA+/- status for Overall Survival (Panel B).  In 
Panel B, multivariable analysis is adjusted for age, body mass index, grade, tumour size, HER2 status, ER status, 
ethnicity and use of taxane chemotherapy. 
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Figure 2 – Time-varying effects of BRCA status on Overall Survival for all TNBC patients (TNBC population) 
 
Time-varying hazard rates by BRCA1 and/or 2 status (BRCA+/-) for Overall Survival (OS) (Panel A); and 
corresponding time-varying hazard ratio for Overall Survival (Panel B). 
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Figure 3 – Overall Survival by BRCA status for all TNBC patients (TNBC population) 
 
Kaplan-Meier plot by BRCA1 and/or 2 status (BRCA+/-) for Overall Survival (OS) (Panel A); and Forest Plot of 
corresponding univariable and multivariable hazard ratios by BRCA+/- status for Overall Survival (Panel B).  In 
Panel B, multivariable analysis is adjusted for age, body mass index, tumour size, ethnicity and use of taxane 
chemotherapy. 
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Appendix 
Appendix Table 1: Recruitment by active sites 
List of recruitment number by all active sites in the reported cohort. 
Appendix Table 2: List of BRCA1 and BRCA2 mutation annotation 
List of 338 pathogenic BRCA1 and BRCA2 variants included in the BRCA+ group 
Appendix Table 3: Cause of death breakdown by BRCA status (analysis population who died) 
List of all causes of death in the reported cohort. 
Appendix Table 4: Multivariable Analyses - Complete-Case Results (analysis population) 
Breakdown of compete-case results for each multivariable analysis carried out on the analysis 
population. 
Appendix Table 5: Multivariable Analyses - Complete-Case Results (TNBC population) 
Breakdown of compete-case results for each multivariable analysis carried out on the TNBC 
population. 
  
Appendix Figure 1 – Flow diagram of the POSH cohort 
 
Flow diagram of the POSH cohort. 
Appendix Figure 2 – Distant Disease Free Survival by BRCA status for all patients (analysis population) 
 
Kaplan-Meier plot by BRCA1 and/or 2 status (BRCA+/-) for Distant Disease Free Survival (OS) (Panel A); and 
Forest Plot of corresponding univariable and multivariable hazard ratios by BRCA+/- status for Distant Disease 
Free (Panel B).  In Panel B, multivariable analysis is adjusted for age, body mass index, grade, tumour size, 
HER2 status, ER status, ethnicity and use of taxane chemotherapy. 
Appendix Figure 3 – Overall Survival by BRCA1 status for all patients (analysis population) 
 
Kaplan-Meier plot by BRCA1 status (BRCA1+/-) for Overall Survival (OS) (Panel A); and Forest Plot of 
corresponding univariable and multivariable hazard ratios by BRCA1+/- status for Overall Survival (Panel B).  In 
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Panel B, multivariable analysis is adjusted for age, body mass index, grade, tumour size, HER2 status, ER status, 
ethnicity and use of taxane chemotherapy. 
Appendix Figure 4 – Overall Survival by BRCA2 status for all patients (analysis population) 
 
Kaplan-Meier plot by BRCA2 status (BRCA2+/-) for Overall Survival (OS) (Panel A); and Forest Plot of 
corresponding univariable and multivariable hazard ratios by BRCA2+/- status for Overall Survival (Panel B).  In 
Panel B, multivariable analysis is adjusted for age, body mass index, grade, tumour size, HER2 status, ER status, 
ethnicity and use of taxane chemotherapy. 
Appendix Figure 5 – Distant Disease Free Survival by BRCA status for all TNBC patients (TNBC population) 
 
Kaplan-Meier plot by BRCA1 and/or 2 status (BRCA+/-) for Distant Disease Free Survival (OS) (Panel A); and 
Forest Plot of corresponding univariable and multivariable hazard ratios by BRCA+/- status for Distant Disease 
Free Survival (Panel B).  In Panel B, multivariable analysis is adjusted for age, body mass index, tumour size, 
ethnicity and use of taxane chemotherapy. 
Appendix Figure 6 – Overall Survival by BRCA status for all patients, adjusting for time to blood draw 
(analysis population) 
 
Forest Plot of univariable and multivariable hazard ratios by BRCA+/- status for Overall Survival (OS), adjusting 
for time to blood draw.  Multivariable analysis is also adjusted for age, body mass index, grade, tumour size, 
HER2 status, ER status, ethnicity and use of taxane chemotherapy. 
Appendix Figure 7 – Multivariable Analyses - Proportional hazards tests  
 
Proportional hazards (PH) test results for the main comparators for: (A) Overall Survival (OS) by BRCA status – 
analysis population (PH assumption met); (B) Distant disease free survival (DDFS) by BRCA status – analysis 
population (PH assumption met); (C) OS by BRCA1 status – analysis population (PH assumption met); (D) OS by 
BRCA2 status – analysis population (PH assumption met); (E) OS by BRCA status – TNBC population (PH 
assumption not met); (F) DDFS by BRCA status – TNBC  
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Appendix Figure 8 – Overall Survival by BRCA status for TNBC patients not having immediate bilateral 
mastectomies (TNBC population, excluding patients not having immediate bilateral mastectomies) 
 
Forest Plot of univariable and multivariable hazard ratios by BRCA+/- status for Overall Survival (OS).  
Multivariable analysis is adjusted for age, body mass index, tumour size, ethnicity and use of taxane 
chemotherapy. 
Appendix Figure 9 – Overall Survival by BRCA status for TNBC patients who did not develop a new primary 
breast or ovarian cancer (TNBC population, excluding patients who developed a new primary breast or 
ovarian cancer) 
 
Forest Plot of univariable and multivariable hazard ratios by BRCA+/- status for Overall Survival (OS).  
Multivariable analysis is adjusted for age, body mass index, tumour size, ethnicity and use of taxane 
chemotherapy. 
Appendix Methods 1: BRCA1 and BRCA2 gene sequencing and variant calling 
Details of sequencing methodology and annotation of variants. 
Appendix Document 1: Statistical Analysis Plan 
Statistical analysis plan (SAP), approved on 10-May-2016, and formatted for Lancet Oncology Appendix. 
Appendix Document 2: STROBE Checklist 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist. 
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